Inactive Instrument

InVitae Corp Share Price Nyse

Equities

Biotechnology & Medical Research

End-of-day quote Nyse
- - Intraday chart for InVitae Corp
Sales 2021 460M 0 36.67B Sales 2022 516M 0 41.12B Capitalization 452M 0 35.98B
Net income 2021 -379M - -30.19B Net income 2022 -3.11B - -247B EV / Sales 2021 8.98 x
Net Debt 2021 679M 0 54.06B Net Debt 2022 1.2B 0 95.89B EV / Sales 2022 3.21 x
P/E ratio 2021
-8.5 x
P/E ratio 2022
-0.14 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 98.19%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 63 28/06/20
Director of Finance/CFO - 01/10/23
Chief Operating Officer 56 11-12
Members of the board TitleAgeSince
Director/Board Member 67 03/11/15
Chief Executive Officer 66 12/01/10
Director/Board Member 62 31/08/10
More insiders
Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.
Related indices
More about the company